Analysis of the effectiveness and safety of switching from original to biosimilar adalimumab in patients with inflammatory bowel disease
INDEPENDENT POST AUTHORIZATION STUDY
Clinical trial information
- Promoter: PEREZ
- Execution start: 25/06/2021
- End of execution: 30/12/2021
- IP: MARIA DEL MAR MARTIN RODRIGUEZ